Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK Partners with Apple on Clinical Trial Research for RA

By Ryan Bushey | July 19, 2016

Screenshot of the app named GSK PARADE. Source: GSK

Apple’s medical research software ResearchKit is getting a boost from drugmaker GlaxoSmithKline (GSK).

The pharma giant will use the company’s program as a way to kick start recruitment for a trial focusing on rheumatoid arthritis. GSK claims it is the first firm in the pharmaceutical industry to incorporate a tool like this into its research efforts.

GSK created a mobile application using ResearchKit’s framework to spend three months recording the mobility of 300 participants, reported Bloomberg. The app will work in conjunction with a guided wrist exercise that will harness the phone’s sensors for recording motion.

Results of this venture could help GSK create a better, cheaper clinical trial.

“One of the biggest challenges in clinical trials is that it’s hard to engage patients because they might have to take time off work, they often have to travel significant distances and then they’re subjected to a series of measures that can be invasive,” explained Rob DiCicco, the head of GSK’s clinical innovation and digital platforms group, to Bloomberg.

It could cut down on recruitment costs because patients would simply need to enter data, such as physical and emotional symptoms, on their own time using their phones.

However, there are some downsides to this technique, noted FierceBiotech. A risk of bias is involved because iPhones tend to be an expensive purchase so enrollment could be limited. Also, patients could grow tired of continuously inputting information into their phones so there is no guarantee GSK will get a comprehensive overview of the condition after the trial is over.

No specific drug is at the center of this experiment, but DiCicco told Bloomberg he hopes these findings could potentially lead to new measurements for refining clinical trial success or establishing a supplemental tool for collecting data.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE